Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study

Autor: Ian Kracalik, Matthew E Oster, Karen R Broder, Margaret M Cortese, Maleeka Glover, Karen Shields, C Buddy Creech, Brittney Romanson, Shannon Novosad, Jonathan Soslow, Emmanuel B Walter, Paige Marquez, Jeffrey M Dendy, Jared Woo, Amy L Valderrama, Alejandra Ramirez-Cardenas, Agape Assefa, M Jay Campbell, John R Su, Shelley S Magill, David K Shay, Tom T Shimabukuro, Sridhar V Basavaraju, Paula Campbell, Chidera Anugwom, Colenda Arvelo Jefferson, Kimberly Badger, Nastocia Bafford, Chandra Barnes, Stephanie Boles, Emory Collins, Mitesh Desai, Theresa Dulski, Barbara Dyleski, Kathryn Edwards, Melanie Feyereisen, Stephanie Gonsahn, Tchernavia Gregory, Jyothi Gunta, Kara Jacobs Slifka, Charlotte Kabore, Bryan K. Kapella, Susan Karol, Kalah Kennebrew, Nancy Kluisza, Sean Lang, Labretta Lanier Gholston, Marcella Law, Jennifer Lehman, Jacek M. Mazurek, Henraya McGruder, Kiara McNamara, Maria-Luisa Moore, Pedro Moro, John F. Moroney, Oidda Museru, Cassandra Nale, Andi Neiman, Kim Newsome, Erika Odom, Brooke Pantazides, Suchita Patel, Agam Rao, Laura Reynolds, Sonya Robinson, Frederick L. Ruberg, Tammy Schaeffer, Dipesh Solanky, Laurence Sperling, Toscha Stanley, Regina Sullivan, Allan Taylor, Kimberly Thomas, Shayle Thompson, Jigsa Tola, Cuc H. Tran, Steven Wiersma, Kimberly Works

Publikováno v: The Lancet. Childadolescent health. 6(11)

Data on medium-term outcomes in indivduals with myocarditis after mRNA COVID-19 vaccination are scarce. We aimed to assess clinical outcomes and quality of life at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::359b5b926f4a6ba5ddf43cd2bddcbdd8
https://pubmed.ncbi.nlm.nih.gov/36462507